Literature DB >> 23383628

Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany.

J M Kittner1, F Brokamp, B Jäger, W Wulff, B Schwandt, J Jasinski, H Wedemeyer, R E Schmidt, J M Schattenberg, P R Galle, M Schuchmann.   

Abstract

Disclosure is a prerequisite to receive disease-specific social support. However, in the case of a stigmatised disease, it can also lead to discrimination. We aimed to assess disclosure rates of HIV patients and the reactions they encountered in comparison to patients with chronic viral hepatitis or diabetes mellitus and patients' general perception of disease-specific discrimination. We constructed a self-report questionnaire, anonymously assessing the size of the social environment, the persons who had been informed, and the experienced reactions as perceived by the disclosing patients, to be rated on 1-4 point Likert scales. In addition, patients were asked whether they perceive general discrimination in Germany. One hundred and seventy-one patients were asked to participate. Five rejected, thus questionnaires from 83 patients with HIV, 42 patients with chronic viral hepatitis B (n = 9) or C (n = 33), and 41 patients with insulin-dependent diabetes mellitus (type I n = 14, type II n = 27) were analysed. Whereas the size of the social environment did not differ, HIV-infected patients were least likely to disclose their disease (60.7%, SD ± 31.9) to their social environment as compared to patients with chronic viral hepatitis (84.2 ± 23.3%, p<0.0001), or diabetes mellitus (94.4 ± 10.3%, p<0.0001), respectively. Within the HIV patient group, the mean disclosure rate was highest to partners (90.9%), followed by the public environment (65.2%), friends (59.4%) and family members (43.8%). HIV patients experienced supportive reactions after 79.3 ± 26.4% of disclosures, which was the case in 91.4 ± 19.6% and 75.7 ± 36.1% of patients with hepatitis or diabetes mellitus, respectively. 69.5% of HIV patients stated to perceive general discrimination in Germany. We conclude that HIV patients had experienced supportive reactions after the majority of disclosures, but the low rate points out that their information strategy had been very selective. Societal discrimination of HIV patients is still an issue and needs to be further addressed.

Entities:  

Mesh:

Year:  2013        PMID: 23383628     DOI: 10.1080/09540121.2013.764387

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  6 in total

1.  Hepatitis B Infection: A Mixed Methods of Disclosure Pattern and Social Problems in the Nigerian Family.

Authors:  Olusegun Adekanle; Akinwumi Oluwole Komolafe; Samuel A Olowookere; Oluwasegun Ijarotimi; Dennis Amajuoyi Ndububa
Journal:  J Patient Exp       Date:  2019-03-07

2.  Depression, Anxiety, Psychological Symptoms and Health-Related Quality of Life in People Living with HIV.

Authors:  Shaohang Cai; Lili Liu; Xiaolu Wu; Ye Pan; Tao Yu; Hongjie Ou
Journal:  Patient Prefer Adherence       Date:  2020-08-25       Impact factor: 2.711

3.  Factors Associated with Attrition: Analysis of an HIV Clinic in Japan.

Authors:  Chieko Hashiba; Mayumi Imahashi; Junji Imamura; Masashi Nakahata; Ayumi Kogure; Hideto Takahashi; Yoshiyuki Yokomaku
Journal:  J Immigr Minor Health       Date:  2021-04

4.  Disclosure and Experienced Social Support are not Related to Anxiety or Depression in a German HIV Patient Cohort.

Authors:  Jens M Kittner; Felix Brokamp; Thomas Thomaidis; Reinhold E Schmidt; Jörg Wiltink; Peter R Galle; Burkard Jäger
Journal:  Infect Chemother       Date:  2014-06-20

5.  Effect of 'lifestyle stigma' on public support for NHS-provisioned pre-exposure prophylaxis (PrEP) and preventative interventions for HPV and type 2 diabetes: a nationwide UK survey.

Authors:  Timothy Hildebrandt; Leticia Bode; Jessica S C Ng
Journal:  BMJ Open       Date:  2019-08-22       Impact factor: 2.692

6.  "To die is better than to tell": reasons for and against disclosure of chronic hepatitis B status in Ghana.

Authors:  Charles Ampong Adjei; Sarah E Stutterheim; Florence Naab; Robert A C Ruiter
Journal:  BMC Public Health       Date:  2020-05-12       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.